LENVIMA

( ARTG ) Endometrial carcinoma LENVIMA, in combination with pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation., ‍‍‍‍‍‍​​​‍​​​​​​ Differentiated thyroid cancer (DTC) LENVIMA is indicated for the treatment of patients with progressive, locally advanced or metastatic, radioactive iodine (RAI) refractory differentiated thyroid cancer (DTC).,Renal cell carcinoma (RCC) LENVIMA, in combination with pembrolizumab, is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).,LENVIMA, in combination with everolimus, is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) whose disease has progressed following one prior vascular endothelial growth factor targeted therapy.,Hepatocellular carcinoma (HCC) LENVIMA is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).